Celgene Corporation Emerges as Biotech's Shrewdest, Nimblest Dealmaker

Published: Aug 06, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Celgene is best known for taking a notoriously dangerous compound, thalidomide, and turning a derivative into a hugely successful cancer drug. But what fewer people may realize is that it is fast building the biotech industry’s best network of partnerships with innovators. This feels odd to say, even though Celgene (NASDAQ: CELG) has been a big success for a long time, and now has a market valuation of more than $60 billion.

Help employers find you! Check out all the jobs and post your resume.

Back to news